Natixis Advisors LLC Sells 12,843 Shares of Lantheus Holdings, Inc. (NASDAQ:LNTH)

Natixis Advisors LLC cut its holdings in shares of Lantheus Holdings, Inc. (NASDAQ:LNTH - Free Report) by 27.7% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 33,602 shares of the medical equipment provider's stock after selling 12,843 shares during the period. Natixis Advisors LLC's holdings in Lantheus were worth $3,006,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently made changes to their positions in LNTH. Wilmington Savings Fund Society FSB purchased a new position in Lantheus during the 3rd quarter worth $25,000. Kestra Investment Management LLC bought a new position in shares of Lantheus during the fourth quarter valued at about $27,000. UMB Bank n.a. lifted its position in shares of Lantheus by 31.5% during the fourth quarter. UMB Bank n.a. now owns 559 shares of the medical equipment provider's stock valued at $50,000 after purchasing an additional 134 shares in the last quarter. World Investment Advisors LLC purchased a new position in Lantheus during the third quarter worth about $60,000. Finally, Parkside Financial Bank & Trust grew its position in Lantheus by 49.4% in the 4th quarter. Parkside Financial Bank & Trust now owns 847 shares of the medical equipment provider's stock worth $76,000 after purchasing an additional 280 shares in the last quarter. Institutional investors and hedge funds own 99.06% of the company's stock.

Lantheus Price Performance

NASDAQ LNTH traded down $1.39 during trading hours on Thursday, reaching $97.04. 681,764 shares of the stock traded hands, compared to its average volume of 930,255. The stock has a 50 day simple moving average of $93.01 and a two-hundred day simple moving average of $96.47. Lantheus Holdings, Inc. has a 1 year low of $58.16 and a 1 year high of $126.89. The company has a market cap of $6.65 billion, a price-to-earnings ratio of 16.15 and a beta of 0.38.

Lantheus (NASDAQ:LNTH - Get Free Report) last announced its quarterly earnings data on Thursday, February 27th. The medical equipment provider reported $1.34 earnings per share for the quarter, missing analysts' consensus estimates of $1.57 by ($0.23). The firm had revenue of $391.11 million for the quarter, compared to analysts' expectations of $376.61 million. Lantheus had a net margin of 28.57% and a return on equity of 44.29%. On average, sell-side analysts forecast that Lantheus Holdings, Inc. will post 6.01 EPS for the current fiscal year.

Insider Transactions at Lantheus

In related news, Director James H. Thrall sold 1,000 shares of Lantheus stock in a transaction on Wednesday, January 15th. The shares were sold at an average price of $94.76, for a total value of $94,760.00. Following the transaction, the director now owns 33,207 shares in the company, valued at $3,146,695.32. This trade represents a 2.92 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Mary Anne Heino sold 53,107 shares of the business's stock in a transaction on Monday, March 3rd. The stock was sold at an average price of $94.35, for a total transaction of $5,010,645.45. Following the completion of the sale, the director now directly owns 440,399 shares of the company's stock, valued at $41,551,645.65. This represents a 10.76 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 64,109 shares of company stock worth $6,110,806. 1.50% of the stock is currently owned by insiders.

Analysts Set New Price Targets

LNTH has been the topic of several recent analyst reports. The Goldman Sachs Group initiated coverage on shares of Lantheus in a research report on Wednesday, December 18th. They set a "buy" rating and a $143.00 target price on the stock. Truist Financial lifted their price target on Lantheus from $120.00 to $127.00 and gave the stock a "buy" rating in a report on Thursday, February 27th. B. Riley decreased their target price on Lantheus from $127.00 to $122.00 and set a "buy" rating for the company in a research report on Friday, March 21st. Finally, JMP Securities reaffirmed a "market outperform" rating and set a $112.00 price target on shares of Lantheus in a research report on Tuesday, January 14th. One research analyst has rated the stock with a hold rating and seven have assigned a buy rating to the stock. According to data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and an average target price of $129.43.

Lantheus Company Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.